**Technology Advisory Committee A Interests Register**

**Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [Review of TA540] [ID5084]**

**Publication Date: 01/05/2024**

| Name | Role with NICE | Type of interest | Description of interest | Interestdeclared | Comments |
| --- | --- | --- | --- | --- | --- |
| Prithwiraj Das | Committee C Member | Indirect - Financial Interests | Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR ltd. I have not worked on these products/indications in the last 12+ months.  | 05/02/2024 | It was agreed that Prithwiraj’s declaration would not prevent him from being part of the committee. |
| Dr Patrick De Barr | Committee A Member | Direct – financial interests | Patrick received paid employment from a company who have a PD1 antibody under development, however this is in a different indication. | 25/01/2024 | It was agreed that Patrick’s declaration would not prevent him from being part of the committee. |
| Beth Phillips | Clinical Expert | Indirect – Financial | Takeda (brentuximab vedotin)Speakers fees: ASH highlights meeting (educational meeting, no direct relation to specific products); 16/1/2023; £1676.50Travel/conference registration: ISHL and virtual ASH attendance: 22/10/22 – 13/12/22; amount not knownResearch funding via the University of Manchester for RADAR clinical trial (as co-investigator, CI: Prof John Radford): 10/2020 – ongoing; £3,860,091 | 13/02/2024 | It was agreed that Beth’s declaration would not prevent her from providing expert comments to the committee. |